GO:0019966 interleukin-1 binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0019966 (interleukin-1 binding) is a molecular function defined as binding to interleukin-1, encompassing the interaction of IL-1 family ligands with their receptors and soluble binding proteins.
• The interleukin-1 family includes IL-1α, IL-1β, IL-1Ra, IL-18, IL-33, IL-36, and IL-37, all of which engage binding partners through related structural folds.
• Interleukin-1 binding is the first step in IL-1 signal transduction, which drives NF-κB and MAPK activation and is central to innate immunity and inflammation.
• Dysregulated interleukin-1 binding contributes to autoimmune diseases, cancer progression, and neuroinflammation, making it a major therapeutic target.
• Key binding proteins include IL1R1, IL1R2, IL1RAP, IL1RL1, IL18R1, and the soluble antagonist IL1RN, each with distinct binding affinities and signaling outcomes.
• CRISPR-based knockout, knock-in, and point-mutation models enable precise dissection of interleukin-1 binding interfaces and downstream signaling in disease-relevant cell types.
Description
Interleukin-1 binding (GO:0019966) is a molecular function that describes the physical interaction between interleukin-1 ligands and their cognate binding proteins, including cell-surface receptors and soluble antagonists. This function is the initiating event for one of the most potent inflammatory signaling cascades in mammals, and it is conserved across the interleukin-1 family of cytokines. Researchers study interleukin-1 binding to understand how immune cells sense danger signals, how chronic inflammation is sustained in disease, and how therapeutic blockade of this interaction can be achieved.
interleukin-1 binding At A Glance
| GO ID | GO:0019966 |
|---|---|
| GO term | interleukin-1 binding |
| Ontology | molecular_function |
| Synonym | IL-1 binding |
| Definition | Binding to interleukin-1. |
| Major function | Mediates the initial recognition of interleukin-1 ligands by receptors and soluble binding proteins, initiating inflammatory signaling. |
| Representative ligands | IL-1α, IL-1β, IL-1Ra, IL-18, IL-33, IL-36, IL-37. |
| Representative receptors | IL1R1, IL1R2, IL1RAP, IL1RL1, IL18R1. |
| Downstream pathways | NF-κB and MAPK signaling. |
| Disease relevance | Autoinflammatory diseases, autoimmune disorders, cancer, and neuroinflammation. |
What Is GO:0019966?
According to the Gene Ontology, GO:0019966 (interleukin-1 binding) is defined as binding to interleukin-1. In practical terms, this molecular function encompasses any selective and non-covalent interaction between an interleukin-1 family ligand and a protein partner, such as a membrane receptor, a decoy receptor, or a soluble antagonist. This binding event is the molecular prerequisite for receptor dimerization, intracellular signaling, and the downstream inflammatory responses attributed to interleukin-1.
Why Is interleukin-1 binding Important in Cell Biology?
Interleukin-1 binding is important because it governs the first molecular step of a signaling axis that controls fever, acute-phase responses, immune cell activation, and tissue remodeling. Because this binding event is extracellular and highly specific, it is an attractive target for biologic drugs and small-molecule inhibitors, and it serves as a paradigm for understanding cytokine-receptor recognition.
• Initiates NF-κB and MAPK signaling cascades that drive inflammatory gene expression.
• Central to innate immune sensing of infection and tissue damage.
• Dysregulated in rheumatoid arthritis, atherosclerosis, and other chronic inflammatory diseases.
• Contributes to tumor microenvironment inflammation and cancer progression.
• Mediates neuroinflammation through IL-1 binding sites on astrocytes and other glial cells.
• Provides validated drug targets such as IL1R1 and IL1RN for therapeutic intervention.
• Serves as a structural model for the broader interleukin-1 family of cytokines.
• Enables experimental dissection of ligand-receptor specificity using CRISPR-edited cell models.
• Links innate immunity to adaptive immune responses through cytokine-mediated crosstalk.
• Underpins biomarker and therapeutic strategies in autoinflammatory syndromes.
Molecular Mechanism of interleukin-1 binding
Ligand recognition and receptor engagement
In simple terms: Interleukin-1 molecules dock onto specific receptor proteins on the cell surface.
Interleukin-1 binding begins when IL-1 family ligands, such as IL-1α and IL-1β, recognize the extracellular domains of their cognate receptors. The interaction is mediated by a conserved β-trefoil fold in the ligand that engages immunoglobulin-like domains in the receptor, forming a high-affinity complex. This initial recognition event is the molecular basis of GO:0019966 and determines whether a cell will respond to interleukin-1.
Ternary complex assembly and co-receptor recruitment
In simple terms: After the first receptor binds, a second receptor joins to form a signaling-competent complex.
Following ligand binding to the primary receptor, a co-receptor such as IL1RAP is recruited to form a ternary signaling complex. This assembly is essential for juxtaposing intracellular TIR domains, which then serve as scaffolds for adaptor proteins. The stoichiometry and geometry of this complex are dictated by the binding interfaces of the interleukin-1 ligand and its receptors.
Soluble decoy and antagonist binding
In simple terms: Some proteins bind interleukin-1 without triggering signaling, acting as decoys or blockers.
IL1R2 functions as a decoy receptor that binds interleukin-1 but lacks a functional signaling domain, thereby sequestering the ligand. Similarly, IL1RN (interleukin-1 receptor antagonist) binds IL1R1 with high affinity but does not recruit IL1RAP, preventing signal initiation. These competitive binding events modulate the effective concentration of free interleukin-1 and are integral to the regulation of GO:0019966.
Binding specificity within the interleukin-1 family
In simple terms: Different interleukin-1 family members bind different receptors, creating specific biological outcomes.
The interleukin-1 family comprises multiple ligands, including IL-18, IL-33, IL-36, and IL-37, each with distinct binding partners. For example, IL-33 binds IL1RL1 (ST2), while IL-18 binds IL18R1, and these interactions are structurally related to but functionally distinct from IL-1α/β binding. Computational studies of the interleukin-1 family have revealed putative binding sites that explain ligand-receptor selectivity.
Structural determinants of binding affinity
In simple terms: The shape and chemical properties of the binding interface determine how tightly interleukin-1 sticks to its partner.
High-resolution structural and computational analyses have identified key residues in interleukin-1 ligands that mediate receptor contact and affinity. Mixed-solvent molecular dynamics simulations of the interleukin-1 family have highlighted conserved and variable binding-site regions that contribute to specificity. These structural determinants are critical for designing mutations that disrupt or enhance interleukin-1 binding in experimental models.
Key Genes Involved in GO:0019966 interleukin-1 binding
The following genes encode the principal ligands, receptors, and regulatory proteins that participate in or modulate interleukin-1 binding (GO:0019966).
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL1B | Encodes interleukin-1 beta, a major ligand that binds IL1R1 | Central to inflammatory signaling; knockout and knock-in models used to study binding specificity. |
| IL1A | Encodes interleukin-1 alpha, a ligand that binds IL1R1 | Membrane-bound and secreted forms; studied for differential binding and signaling. |
| IL1RN | Encodes interleukin-1 receptor antagonist, a competitive binding inhibitor | Therapeutic relevance in autoinflammatory diseases; used in binding competition assays. |
| IL1R1 | Encodes the primary signaling receptor for IL-1 | Key target for knockout and point-mutation studies of binding interfaces. |
| IL1R2 | Encodes a decoy receptor that binds IL-1 without signaling | Used to study ligand sequestration and regulation of free IL-1 levels. |
| IL1RAP | Encodes the co-receptor required for ternary complex formation | Essential for signal transduction; knockout models abolish IL-1 responses. |
| IL1RL1 | Encodes ST2, the receptor for IL-33 | Studied for IL-33 binding and allergic inflammation. |
| IL18R1 | Encodes the receptor for IL-18 | Relevant to Th1 responses and IFN-γ production. |
| IL18 | Encodes interleukin-18, a ligand that binds IL18R1 | Involved in inflammasome-mediated inflammation. |
| IL33 | Encodes interleukin-33, a ligand that binds IL1RL1 | Studied in type 2 immunity and tissue repair. |
| IL36G | Encodes interleukin-36 gamma, a ligand in the IL-1 family | Implicated in skin inflammation and keratinocyte signaling. |
| IL37 | Encodes interleukin-37, an anti-inflammatory IL-1 family member | Modulates inflammatory responses through binding interactions. |
| MYD88 | Encodes the adaptor protein recruited after IL-1 receptor binding | Knockout abolishes IL-1 signaling; used in pathway dissection. |
| IRAK4 | Encodes a kinase activated downstream of IL-1 binding | Point mutations used to study signaling propagation. |
| NFKB1 | Encodes a transcription factor activated by IL-1 binding | Reporter and knockout models assess downstream transcriptional output. |
| MAPK14 | Encodes p38 MAPK, a kinase activated by IL-1 binding | Used to study stress-activated signaling branches. |
| TRAF6 | Encodes an E3 ubiquitin ligase essential for IL-1 signaling | Knockout models define its role in post-binding events. |
| GSDME | Encodes gasdermin E, involved in IL-1 family cytokine release | Studied in the context of IL-36γ release from keratinocytes. |
How Is interleukin-1 binding Regulated?
Interleukin-1 binding is regulated at multiple levels, including the availability of free ligand, the expression levels of signaling versus decoy receptors, and the presence of soluble antagonists such as IL1RN. IL1R2 acts as a decoy receptor that competes with IL1R1 for ligand binding, thereby dampening signaling. Additionally, the release of IL-1 family cytokines can be controlled by inflammasome activation and gasdermin-mediated pore formation, which affects the extracellular pool of ligands available for binding. These regulatory mechanisms ensure that interleukin-1 binding is tightly coupled to the inflammatory context.
interleukin-1 binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL1B | Autoinflammatory fever syndromes | Knockout and point-mutation cell lines to assess ligand-receptor binding. |
| IL1RN | DIRA (deficiency of IL-1 receptor antagonist) | Knock-in of patient mutations to study loss of binding competition. |
| IL1R1 | Rheumatoid arthritis and inflammation | CRISPR knockout in synovial fibroblasts to measure IL-1 binding and signaling. |
| IL1RL1 | Allergic asthma and type 2 inflammation | Overexpression and knockout models for IL-33 binding studies. |
| IL36G | Psoriasis and skin inflammation | Keratinocyte knockout and reporter lines to track IL-36γ release and binding. |
Interleukin-1 binding in autoinflammatory and autoimmune diseases
Dysregulated interleukin-1 binding is a hallmark of autoinflammatory syndromes, where excessive IL-1β signaling drives fever, rash, and joint inflammation. In rheumatoid arthritis and other autoimmune conditions, elevated IL-1 binding to IL1R1 on synovial cells perpetuates chronic inflammation. Therapeutic agents that block interleukin-1 binding, such as anakinra (IL1RN), have validated this axis as a drug target.
Interleukin-1 binding in cancer
Interleukin-1 binding within the tumor microenvironment promotes angiogenesis, immunosuppression, and metastasis. IL-1β binding to IL1R1 on tumor and stromal cells activates NF-κB, which supports pro-tumorigenic gene expression. Targeting interleukin-1 binding has shown promise in reducing tumor-associated inflammation in preclinical models.
Interleukin-1 binding in neuroinflammation
Interleukin-1 binding sites on astrocytes and other glial cells mediate neuroinflammatory responses in the central nervous system. Elevated IL-1 binding in the brain has been associated with neurodegenerative conditions and acute neuroinflammation. Understanding these binding events is critical for developing CNS-targeted anti-inflammatory strategies.
Interleukin-1 family binding in skin inflammation
IL-36γ, a member of the interleukin-1 family, is released from keratinocytes upon activation of RIG-I-like receptor signaling and gasdermin E, and its binding to IL-36 receptor contributes to skin inflammation. This highlights the broader relevance of interleukin-1 binding functions beyond IL-1α/β in epithelial immunity.
From interleukin-1 binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate receptor mediate interleukin-1 binding? | CRISPR knockout of the receptor gene followed by ligand-binding assays. |
| Which residues are required for high-affinity binding? | Point-mutation knock-in of ligand or receptor at predicted interface residues. |
| Can a tagged receptor be used to track binding dynamics? | Knock-in of an epitope-tagged receptor for imaging and immunoprecipitation. |
| Does overexpression of a decoy receptor reduce signaling? | Overexpression of IL1R2 or IL1RN in reporter cell lines. |
| What is the transcriptional output of interleukin-1 binding? | NF-κB reporter knock-in and RNA-seq in edited cells. |
| How does a disease-associated variant affect binding? | Knock-in of the variant allele and comparison of binding affinity. |
How to Study the interleukin-1 binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding assay | Direct ligand-receptor binding affinity | Characterizing IL-1 binding to IL1R1 on cell membranes. |
| Surface plasmon resonance | Kinetic rate constants and affinity | Comparing wild-type and mutant receptor binding. |
| NF-κB luciferase reporter | Transcriptional activation downstream of binding | Functional validation of interleukin-1 binding events. |
| Co-immunoprecipitation | Physical interaction between ligand and receptor | Detecting ternary complex formation. |
| Molecular dynamics simulation | Binding-site stability and ligand contacts | Predicting residues critical for IL-1 family binding. |
| Flow cytometry | Cell-surface receptor expression and ligand binding | Quantifying binding on primary immune cells. |
| RNA-seq | Global transcriptional changes after binding | Identifying downstream inflammatory gene programs. |
| CRISPR screening | Genes required for interleukin-1 binding or response | Unbiased discovery of novel binding regulators. |
Ligand-binding assays
Radiolabeled or fluorescently labeled interleukin-1 ligands are used to measure direct binding to receptors on cells or in purified systems. Saturation and competition binding experiments quantify affinity and specificity, and are foundational for studying GO:0019966.
Surface plasmon resonance and biophysical binding
Surface plasmon resonance (SPR) and isothermal titration calorimetry provide real-time kinetic and thermodynamic parameters for interleukin-1 binding to receptors or antagonists. These methods are used to validate structural predictions and to screen for binding-modulating mutations.
Transcriptional reporter assays
NF-κB or MAPK-responsive luciferase reporters are used to measure the functional consequence of interleukin-1 binding in cells. Combining these reporters with CRISPR-edited receptors allows causal linkage between binding and downstream transcription.
Structural and computational modeling
X-ray crystallography, cryo-EM, and molecular dynamics simulations reveal the atomic details of interleukin-1 binding interfaces. Mixed-solvent molecular dynamics has been applied to the interleukin-1 family to identify putative binding sites and guide mutagenesis.
How CRISPR Can Be Used to Study GO:0019966 interleukin-1 binding
Knockout
CRISPR knockout of IL1R1, IL1RAP, or MYD88 abolishes interleukin-1 binding and downstream signaling, providing a clean background to test receptor specificity. Knockout cell lines are essential for confirming that a candidate gene is required for GO:0019966 activity.
Point Mutation
Point mutations introduced at predicted ligand-receptor interfaces allow precise mapping of residues that contribute to binding affinity and specificity. These models are used to distinguish binding defects from signaling defects.
Knock-in
Knock-in of epitope tags, fluorescent proteins, or disease-associated variants enables tracking of receptor localization and binding dynamics in live cells. Tagged knock-in models are particularly useful for imaging interleukin-1 binding events.
Overexpression
Overexpression of decoy receptors such as IL1R2 or the antagonist IL1RN can sequester interleukin-1 and reduce signaling, providing a gain-of-function approach to study regulation of binding. Overexpression models also help quantify the stoichiometry of ligand-receptor interactions.
How EDITGENE Supports interleukin-1 binding Research
Researchers studying interleukin-1 binding-related genes often need to determine whether a candidate gene is causally involved in ligand recognition, receptor assembly, or downstream signaling. EDITGENE provides end-to-end CRISPR cell model services to accelerate this discovery process.
Contact EDITGENE today to design your custom CRISPR model for interleukin-1 binding research.
Frequently Asked Questions About interleukin-1 binding
What is GO:0019966?
GO:0019966 is the Gene Ontology molecular function term for interleukin-1 binding, defined as binding to interleukin-1.
What genes are involved in interleukin-1 binding?
Key genes include IL1B, IL1A, IL1RN, IL1R1, IL1R2, IL1RAP, IL1RL1, IL18R1, and IL18, among others.
What is the function of interleukin-1 binding?
It initiates receptor complex assembly and downstream NF-κB and MAPK signaling, driving inflammatory responses.
Which receptors bind interleukin-1?
IL1R1 is the primary signaling receptor, IL1R2 is a decoy receptor, and IL1RAP is the co-receptor required for signaling.
How is interleukin-1 binding regulated?
It is regulated by soluble antagonists like IL1RN, decoy receptors like IL1R2, and the availability of free ligand.
What diseases are associated with interleukin-1 binding?
Autoinflammatory syndromes, rheumatoid arthritis, cancer, and neuroinflammation are linked to dysregulated interleukin-1 binding.
How can CRISPR be used to study interleukin-1 binding?
CRISPR knockout, knock-in, and point mutations allow precise dissection of ligand-receptor interactions and downstream signaling.
What methods measure interleukin-1 binding?
Radioligand binding, surface plasmon resonance, co-immunoprecipitation, and reporter assays are commonly used.
Is IL-33 part of the interleukin-1 binding family?
Yes, IL-33 is an interleukin-1 family cytokine that binds IL1RL1 (ST2) and shares structural features with IL-1.
What is the role of IL1RN in interleukin-1 binding?
IL1RN encodes a competitive antagonist that binds IL1R1 without recruiting the co-receptor, thereby blocking signaling.
Conclusion
Interleukin-1 binding (GO:0019966) is a fundamental molecular function that governs the initiation of inflammatory signaling by the interleukin-1 family of cytokines. Its central role in immunity and disease makes it a prime target for both basic research and therapeutic development. Advances in CRISPR-based cell modeling and structural biology continue to refine our understanding of the binding interfaces and regulatory mechanisms that control this function.
References
- 1. Arend WP. 1993. Interleukin-1 receptor antagonist.. Adv Immunol 54:167-227 PMID: 8379462
- 2. Bankers-Fulbright JL et al.. 1996. Interleukin-1 signal transduction.. Life Sci 59(2):61-83 PMID: 8699924
- 3. MacDonald HR et al.. 1987. The interleukin-1/interleukin-1-receptor interaction.. Ann Inst Pasteur Immunol 138(3):482-5 PMID: 2958019
- 4. Keller J et al.. 2025. LL37 complexed to double-stranded RNA induces RIG-I-like receptor signalling and Gasdermin E activation facilitating IL-36γ release from keratinocytes.. Cell Death Dis 16(1):198 PMID: 40121229
- 5. Boraschi D et al.. 2013. The interleukin-1 receptor family.. Semin Immunol 25(6):394-407 PMID: 24246227
- 6. Ban EM et al.. 1993. Interleukin-1 binding sites on astrocytes.. Neuroscience 52(3):725-33 PMID: 8450969
- 7. Mai TT et al.. 2024. Toward Unveiling Putative Binding Sites of Interleukin-33: Insights from Mixed-Solvent Molecular Dynamics Simulations of the Interleukin-1 Family.. J Phys Chem B 128(35):8362-8375 PMID: 39178050
- 8. Dinarello CA et al.. 2013. Interleukin-37.. Semin Immunol 25(6):466-8 PMID: 24275599
